[1]
Grant, S.M.; Clissold, S.P. Itraconazole: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in superficial and systemic mycoses. Drugs, 1989, 37(3), 310-344.
[2]
Lortholary, O.; Denning, D.W.; Dupont, B. Endemic mycoses: A treatment update. J. Antimicrob. Chemother., 1999, 43(3), 321-331.
[3]
Van Cauteren, H.; Heykants, J.; De Coster, R.; Cauwenbergh, G. Itraconazole: Pharmacologic studies in animals and humans. Rev. Infect. Dis., 1987, 9(Suppl. 1), S43-S46.
[4]
Jung, J.Y.; Yoo, S.D.; Lee, S.H.; Kim, K.H.; Yoon, D.S.; Lee, K.H. Enhanced solubility and dissolution rate of itraconazole by a solid dispersion technique. Int. J. Pharm., 1999, 187(2), 209-218.
[5]
Heykants, J.; Van Peer, A.; Van de Velde, V.; Van Rooy, P.; Meuldermans, W.; Lavrijsen, K.; Woestenborghs, R.; Van Cutsem, J.; Cauwenbergh, G. The clinical pharmacokinetics of itraconazole: An overview. Mycoses, 1989, 32(Suppl. 1), 67-87.
[6]
Maghraby, G.M. El.; Alomrani, A.H. Synergistic enhancement of itraconazole dissolution by ternary system formation with pluronic F68 and Hydroxypropylmethylcellulose. Sci. Pharm., 2009, 77(2), 401-417.
[7]
Janssens, S.; de Armas, H.N.; Remon, J.P.; Van den Mooter, G. The use of a new hydrophilic polymer, Kollicoat IR® in the formulation of solid dispersions of Itraconazole. Eur. J. Pharm. Sci., 2007, 30(3-4), 288-294.
[8]
Ye, G.; Wang, S.; Heng, P.W.S.; Chen, L.; Wang, C. Development and optimization of solid dispersion containing pellets of itraconazole prepared by high shear pelletization. Int. J. Pharm., 2007, 337(1-2), 80-87.
[9]
Wang, X.; Michoel, A.; Van den Mooter, G. Solid state characteristics of ternary solid dispersions composed of PVP VA64, Myrj 52 and itraconazole. Int. J. Pharm., 2005, 303(1-2), 54-61.
[10]
Janssens, S.; Nagels, S.; de Armas, H.N.; D’Autry, D.; Van Schepdael, A.; Van den Mooter, G. Formulation and characterization of ternary solid dispersions made up of Itraconazole and two excipients, TPGS 1000 and PVPVA 64, that were selected based on a supersaturation screening study. Eur. J. Pharm. Biopharm., 2008, 69(1), 158-166.
[11]
Janssens, S.; Roberts, C.; Smith, E.F.; Van den Mooter, G. Physical stability of ternary solid dispersions of itraconazole in polyethyleneglycol6000/hydroxypropyl methyl cellulose 2910 E5 blends. Int. J. Pharm., 2008, 355(1-2), 100-107.
[12]
Hassan, H.A.; Al-Marzouqi, A.H.; Jobe, B.; Hamza, A.A.; Ramadan, G.A. Enhancement of dissolution amount and in vivo bioavailability of itraconazole by complexation with β-cyclodextrin using supercritical carbon dioxide. J. Pharm. Biomed. Anal., 2007, 45(2), 243-250.
[13]
Lee, S.Y.; Jung, I.; Kim, J.K.; Lim, G.B.; Ryu, J.H. Preparation of itraconazole/HP-β-CD inclusion complexes using supercritical aerosol solvent extraction system and their dissolution characteristics. J. Supercrit. Fluids, 2008, 44(3), 400-408.
[14]
Mellaerts, R.; Mols, R.; Jammaer, J.A.G.; Aerts, C.A.; Annaert, P.; Van Humbeeck, J.; Mooter, G.V.; Augustijns, P.; Martens, J.A. Increasing the oral bioavailability of the poorly water soluble drug itraconazole with ordered mesoporous silica. Eur. J. Pharm. Biopharm., 2008, 69(1), 223-230.
[15]
Hong, J.Y.; Kim, J.K.; Song, Y.K.; Park, J.S.; Kim, C.K. A new self-emulsifying formulation of itraconazole with improved dissolution and oral absorption. J. Control. Release, 2006, 110(2), 332-338.
[16]
Park, M.J.; Ren, S.; Lee, B.J. In vitro and in vivo comparative study of itraconazole bioavailability when formulated in highly soluble self-emulsifying system and in solid dispersion. Biopharm. Drug Dispos., 2007, 28(4), 199-207.
[17]
Panghal, D.; Nagpal, M.; Thakur, G.S.; Arora, S. Dissolution improvement of atorvastatin calcium using modified locust bean gum by the solid dispersion technique. Sci. Pharm., 2013, 82(1), 177-192.
[18]
Nagpal, M.; Rajera, R.; Nagpal, K.; Rakha, P.; Singh, S.K.; Mishra, D.N. Dissolution enhancement of glimepiride using modified gum karaya as a carrier. Int. J. Pharm. Investig., 2012, 2(1), 42-47.
[19]
Gangurde, A.B.; Malode, S.S.; Bhambar, R.S. Preliminary evaluation of neem gum as tablet binder. Ind. J. Pharm. Educ. Res., 2008, 42(4), 344-347.
[20]
Abayomi, T.; Ogunjimi Gbenga, A. Material and Tableting Properties of Azadirachta Indica Gum With Reference to Official Acacia Gum. Acta Pol. Pharm., 2014, 71(1), 107-118.
[21]
Kulkarni, A.P.; Yunus, R.S.; Dehghan, M.H.D. Application of Neem Gum for Aqueous Film Coating of Ciprofloxacin Tablets. Int. J. Appl. Res. Nat. Prod., 2013, 6(3), 11-19.
[22]
Goswamiand, D.S.; Sharma, M. Development of new mucoadhesive polymer from natural source. Asian J. Pharm. Clin. Res, 2012, 5(3), 247-250.
[23]
Abayomi, T.O.; Gbenga, A. Neem Gum as a Binder in a Formulated Paracetamol Tablet with Reference to Acacia Gum BP. AAPS PharmSciTech, 2014, 10(5), 500-510.
[24]
Rodde, M.S.; Divase, G.T.; Devkar, T.B.; Tekade, A.R. Solubility and bioavailability enhancement of poorly aqueous soluble atorvastatin: In vitro, ex vivo, and in vivo studies. BioMed Res. Int., 2014, 2014463895
[25]
Nagpal, M.; Aggarwal, G.; Sharma, P.; Mahan, P.; Thakur, G.S. Neem gum based solid dispersion in development of aceclofenac tablet with enhanced bioavailability. Drug Deliv. Lett., 2017, 7(2), 115-124.
[26]
Schaefer, H.; Redelmeier, T.E. Prediction and measurements of percutaneous absorption. In: Skin Barrier: principles of percutaneous
absorption; Schaefer H, Redelmeier TE, Ed.; Basel, Karge:. , 1996, pp. 118-152.
[27]
Ghosh, T.K.; Pfister, W.R.; Yum, S.I. Transdermal and Topical Drug Delivery Systems; Buffalo Grove, IL: Interpharm Press, 1997, pp. 33-112.
[28]
Aggarwal, G.; Nagpal, M.; Kaur, G. Development and comparison of nanosponge and niosome based gel for the topical delivery of tazarotene. Pharm. Nanotechnol., 2016, 4(3), 213-228.
[29]
Van-Abbe, N.J.; Nicholas, P.; Boon, E. Exaggerated exposure in topical irritancy and sensitization testing. J. Soc. Cosmet. Chem., 1975, 26, 173-187.